Anna Ljung
Chief Executive Officer chez MOBERG PHARMA AB
Fortune : 986 $ au 31/03/2024
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Jørgen Drejer | M | 69 |
Saniona A/S
Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The private company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders. | 13 ans |
Joseph deBethizy | M | 74 |
Saniona A/S
Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The private company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders. | 5 ans |
Thomas Feldthus | M | 64 |
Saniona A/S
Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The private company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders. | 13 ans |
Rikard Akhtarzand | M | 52 | 16 ans | |
Carl Johan Bertil Sundberg | M | 66 |
Saniona A/S
Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The private company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders. | 9 ans |
Palle Christophersen | M | 66 |
Saniona A/S
Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The private company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders. | 13 ans |
Anita Milland | F | 56 | 10 ans | |
Pierandrea Muglia | M | 58 | 1 ans | |
Nikolaj Sørensen | M | 52 | 3 ans | |
Erik Staffan Torstensson | M | 52 | 4 ans | |
Anders Lundmark | M | 66 | 2 ans | |
Lars Fredrik Celsing | M | 57 | 8 ans | |
Markus Jerling | M | 72 | 3 ans | |
Håkan Wallin | M | 62 | 1 ans | |
Karin Nielsen | F | 54 | - | |
Kerstin Valinder-Strinnholm | F | 64 | 2 ans | |
Gunilla Wengström | F | 62 | 5 ans | |
Anders Bröijersén | M | 60 | 1 ans | |
Hanna Rebecca Lovisa Myhrman | F | 32 | 5 ans | |
Mark Beveridge | M | 46 | 9 ans | |
Anker Gunvald Lundemose | M | 63 |
Saniona A/S
Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The private company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders. | - |
Annica Magnusson | F | 61 | 5 ans | |
Johanne Louise Brændgaard | F | 50 | 3 ans | |
Leif Jan Eugen Andersson | M | 67 |
Saniona A/S
Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The private company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders. | - |
Janus Schreiber Larsen | M | 52 | - | |
Fredrik Mella | M | 54 | 2 ans | |
Rudolf Baumgartner | M | 65 | 4 ans | |
Oliver Humlen | M | 33 | 1 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Statistiques
Pays | Relations | % du total |
---|---|---|
Suède | 55 | 72,37% |
Danemark | 7 | 9,21% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Anna Ljung
- Réseau Personnel